Wellington reports 5.07% stake in Protagonist
Wellington Management Group LLP and affiliated entities report beneficial ownership of 3,171,423 shares of Protagonist Therapeutics, Inc. common stock, representing 5.07% of the class as of the event date.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Wellington Management Group LLP and affiliated entities report beneficial ownership of 3,171,423 shares of Protagonist Therapeutics, Inc. common stock, representing 5.07% of the class as of the event date. The firms report no sole voting or dispositive power over these shares.
They disclose shared voting power over 2,542,632 shares and shared dispositive power over 3,171,423 shares, which are held of record by investment-advisory clients. The filing states the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Protagonist.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What ownership stake in PTGX does Wellington report in this Schedule 13G?
Wellington reports beneficial ownership of 3,171,423 shares of Protagonist Therapeutics common stock, representing 5.07% of the outstanding class. These shares are held on behalf of advisory clients through various Wellington investment adviser entities.
Which Wellington entities are reporting beneficial ownership in Protagonist Therapeutics (PTGX)?
The filing lists Wellington Management Group LLP, Wellington Group Holdings LLP, and Wellington Investment Advisors Holdings LLP as reporting persons. They control or own the investment adviser subsidiaries whose clients hold the Protagonist Therapeutics shares.
Is Wellington’s PTGX position intended to influence control of Protagonist Therapeutics?
No. The certification states the securities were acquired and are held in the ordinary course of business and not for the purpose or effect of changing or influencing control of Protagonist Therapeutics.
When did Wellington’s PTGX holdings trigger this Schedule 13G filing?
The date of the event requiring this statement is listed as December 31, 2025. That date marks when Wellington’s beneficial ownership in Protagonist Therapeutics common stock met the reporting threshold.
AI-generated analysis. How Rhea-AI works. Not financial advice.